跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,651 条关于
“NLS-133”
全部
5,651
临床试验
2,966
药物
1,749
机构
207
资讯
729
7个月前
NEXT Life Sciences Advances Two Non-Hormonal Male Contraceptives Into Phase II Clinical Trials
去年
Kadimastem and NLS Pharmaceutics Merge to Advance ALS Therapy AstroRx
去年
Kadimastem and NLS Pharmaceutics Clear Final SEC Hurdle for Merger Creating NewCelX
去年
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
去年
NLS Pharmaceutics and NewAmsterdam Pharma File Mixed Securities Shelves Worth $75M and $500M Respectively
去年
Kadimastem and iTolerance Seek FDA Input for Novel Type 1 Diabetes Therapy, iTOL102
去年
NLS Pharmaceutics Secures $28 Million in Financing to Advance Merger with Kadimastem and Cell Therapy Pipeline
去年
Mazindol ER Shows Promising Dual Action Against Fentanyl Addiction in Preclinical Studies
去年
Context Therapeutics Acquires Rights to BioAtla's Nectin-4 x CD3 TCE, BA3362, for up to $133 Million
去年
BIRD Foundation Approves Additional Funding for iTOL-102 Type 1 Diabetes Cell Therapy Following FDA Pre-IND Meeting
第 1 页,共 73 页
上一页
下一页